Zealand Pharma A/S
http://www.zealandpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zealand Pharma A/S
Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Finance Watch: Two Biopharma IPOs Bring US Total To 17
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Keeping Track: Rybrevant Goes RTOR, Two-Part Review For Dasiglucagon, And CRL For Ultomiris
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice